{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:17:05Z","timestamp":1775711825016,"version":"3.50.1"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.clim.2018.10.016","type":"journal-article","created":{"date-parts":[[2018,10,28]],"date-time":"2018-10-28T17:28:09Z","timestamp":1540747689000},"page":"23-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Targeting cytokines to treat autoinflammatory diseases"],"prefix":"10.1016","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0786-8788","authenticated-orcid":false,"given":"Jonathan S.","family":"Hausmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2018.10.016_bb0005","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0092-8674(00)80721-7","article-title":"Germline mutations in the extracellular domains of the 55\u202fkDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes","volume":"97","author":"McDermott","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.clim.2018.10.016_bb0010","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.3777","article-title":"The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation","volume":"18","author":"Manthiram","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2018.10.016_bb0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/095952879708000106","article-title":"On a form of chronic joint disease in children","volume":"80","author":"Still","year":"1897","journal-title":"Med. Chir. Trans."},{"key":"10.1016\/j.clim.2018.10.016_bb0020","first-page":"1","article-title":"An unusual paroxysmal syndrome, probably allied to recurrent vomiting, with a study of the nitrogen metabolism","author":"Janeway","year":"1908","journal-title":"Arch. Internal"},{"key":"10.1016\/j.clim.2018.10.016_bb0025","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.clim.2018.10.016_bb0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cyto.2015.06.017","article-title":"The interleukin (IL)-1 cytokine family\u2014balance between agonists and antagonists in inflammatory diseases","volume":"76","author":"Palomo","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.clim.2018.10.016_bb0035","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3389\/fimmu.2013.00391","article-title":"The interleukin-1\u03b1 precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines","volume":"4","author":"Kim","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2018.10.016_bb0040","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.coi.2005.06.002","article-title":"Alarmins: chemotactic activators of immune responses","volume":"17","author":"Oppenheim","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.clim.2018.10.016_bb0045","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2018.10.016_bb0050","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1146\/annurev-immunol-032414-112227","article-title":"Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling","volume":"33","author":"de Jesus","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.clim.2018.10.016_bb0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2016.05.001","article-title":"The role of the inflammasome in patients with autoinflammatory diseases","volume":"138","author":"Hoffman","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2018.10.016_bb0060","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0065","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2018.10.016_bb0070","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.4049\/jimmunol.139.5.1546","article-title":"A urine inhibitor of interleukin 1 activity that blocks ligand binding","volume":"139","author":"Seckinger","year":"1987","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2018.10.016_bb0075","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/343336a0","article-title":"Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor","volume":"343","author":"Hannum","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.clim.2018.10.016_bb0080","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1001\/jama.1994.03510470040032","article-title":"Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group","volume":"271","author":"Fisher","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.clim.2018.10.016_bb0085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF00541245","article-title":"Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis","volume":"2","author":"Fontana","year":"1982","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.clim.2018.10.016_bb0095","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.10.016_bb0100","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1002\/art.10688","article-title":"De novoCIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases","volume":"46","author":"Aksentijevich","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.10.016_bb0105","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86336","article-title":"Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology","volume":"1","author":"Harrison","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.clim.2018.10.016_bb0110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.clim.2018.10.016_bb0115","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.10.016_bb0120","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrrheum.2014.127","article-title":"IL-6 biology: implications for clinical targeting in rheumatic disease","volume":"10","author":"Calabrese","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2018.10.016_bb0125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/BOR.0000000000000255","article-title":"The biology behind interleukin-6 targeted interventions","volume":"28","author":"Liu","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.clim.2018.10.016_bb0130","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: a review in rheumatoid arthritis","volume":"77","author":"Dhillon","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.clim.2018.10.016_bb0135","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1312625","article-title":"Activated STING in a vascular and pulmonary syndrome","volume":"371","author":"Liu","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0140","series-title":"The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases","volume":"1893","author":"Coley","year":"1991"},{"key":"10.1016\/j.clim.2018.10.016_bb0145","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80\u202fkDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.clim.2018.10.016_bb0150","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jama.1995.03520360048038","article-title":"Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group","volume":"273","author":"Abraham","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.clim.2018.10.016_bb0155","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nri802","article-title":"Development of anti-TNF therapy for rheumatoid arthritis","volume":"2","author":"Feldmann","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2018.10.016_bb0160","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","article-title":"Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis","volume":"163","author":"Charles","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2018.10.016_bb0165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.coph.2007.06.001","article-title":"Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases","volume":"7","author":"Williams","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.clim.2018.10.016_bb0170","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/art.24458","article-title":"Familial mediterranean fever in the world","volume":"61","author":"Ben-Chetrit","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.10.016_bb0175","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature13449","article-title":"Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome","volume":"513","author":"Xu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.clim.2018.10.016_bb0180","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","article-title":"EULAR recommendations for the management of familial Mediterranean fever","author":"Ozen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.10.016_bb0185","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJM197212212872514","article-title":"Colchicine for familial Mediterranean fever","volume":"287","author":"Goldfinger","year":"1972","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0190","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM198604173141601","article-title":"Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever","volume":"314","author":"Zemer","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0195","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/art.1780340806","article-title":"Long-term colchicine treatment in children with familial mediterranean fever","volume":"34","author":"Zemer","year":"1991","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.10.016_bb0200","first-page":"75","article-title":"Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature","volume":"10","author":"van der Hilst","year":"2016","journal-title":"Biologics"},{"key":"10.1016\/j.clim.2018.10.016_bb0205","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/acr.23446","article-title":"Nationwide experience with off-label use of interleukin-1 targeting treatment in familial Mediterranean fever patients","volume":"70","author":"Akar","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2018.10.016_bb0210","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-157-8-201210160-00003","article-title":"Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial","volume":"157","author":"Hashkes","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0215","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/art.39995","article-title":"Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial","volume":"69","author":"Ben-Zvi","year":"2017","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.10.016_bb0220","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the treatment of autoinflammatory recurrent fever syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0225","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/ng756","article-title":"Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome","volume":"29","author":"Hoffman","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.clim.2018.10.016_bb0230","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13023-016-0542-8","article-title":"Chronic infantile neurological cutaneous and articular (CINCA) syndrome: a review","volume":"11","author":"Finetti","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.clim.2018.10.016_bb0235","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1056\/NEJM200306193482523","article-title":"Interleukin-1-receptor antagonist in the Muckle-Wells syndrome","volume":"348","author":"Hawkins","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0240","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(04)17401-1","article-title":"Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist","volume":"364","author":"Hoffman","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2018.10.016_bb0245","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","article-title":"Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition","volume":"355","author":"Goldbach-Mansky","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0250","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jneuroim.2010.03.022","article-title":"The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates","volume":"223","author":"Fox","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clim.2018.10.016_bb0255","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0260","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1136\/annrheumdis-2013-204877","article-title":"A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease","volume":"74","author":"Sibley","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.10.016_bb0265","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/annrheumdis-2015-207546","article-title":"Recommendations for the management of autoinflammatory diseases","volume":"74","author":"ter Haar","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.10.016_bb0270","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/9691","article-title":"Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome","volume":"22","author":"Houten","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.clim.2018.10.016_bb0275","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/9696","article-title":"Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group","volume":"22","author":"Drenth","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.clim.2018.10.016_bb0280","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2014-206580","article-title":"Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers","author":"Federici","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.10.016_bb0285","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.clim.2012.09.011","article-title":"Mevalonate kinase deficiency, a metabolic autoinflammatory disease","volume":"147","author":"van der Burgh","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2018.10.016_bb0290","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1056\/NEJM198606193142504","article-title":"Mevalonic aciduria--an inborn error of cholesterol and nonsterol isoprene biosynthesis","volume":"314","author":"Hoffmann","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0295","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1136\/ard.2011.149922","article-title":"On-demand anakinra treatment is effective in mevalonate kinase deficiency","volume":"70","author":"Bodar","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.10.016_bb0300","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/rheumatology\/kes097","article-title":"Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency","volume":"51","author":"Galeotti","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2018.10.016_bb0305","article-title":"Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review","author":"Ter Haar","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.10.016_bb0310","first-page":"469","article-title":"Familial Hibernian fever","volume":"51","author":"Williamson","year":"1982","journal-title":"Q. J. Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0315","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1136\/annrheumdis-2013-204184","article-title":"The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever\/EUROTRAPS international registry","volume":"73","author":"Lachmann","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.10.016_bb0320","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.1073\/pnas.0914118107","article-title":"Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome","volume":"107","author":"Simon","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2018.10.016_bb0325","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/art.33416","article-title":"Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study","volume":"64","author":"Bulua","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.10.016_bb0330","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/rheumatology\/kel298","article-title":"Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS)","volume":"46","author":"Jacobelli","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2018.10.016_bb0335","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/rheumatology\/kem243","article-title":"Comment on: failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS)","volume":"47","author":"Siebert","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clim.2018.10.016_bb0340","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/art.23475","article-title":"Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.10.016_bb0345","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/annrheumdis-2015-209031","article-title":"Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study","volume":"76","author":"Gattorno","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.10.016_bb0350","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/art.30215","article-title":"Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab","volume":"63","author":"Vaitla","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.10.016_bb0355","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s00296-015-3305-2","article-title":"Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS)","volume":"35","author":"La Torre","year":"2015","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.clim.2018.10.016_bb0360","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12969-015-0047-3","article-title":"Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity","volume":"13","author":"Nirmala","year":"2015","journal-title":"Pediatr. Rheumatol."},{"key":"10.1016\/j.clim.2018.10.016_bb0365","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","article-title":"Adult-onset Still's disease","volume":"13","author":"Gerfaud-Valentin","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2018.10.016_bb0370","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MD.0000000000000021","article-title":"Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients","volume":"93","author":"Gerfaud-Valentin","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.clim.2018.10.016_bb0375","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0380","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.10.016_bb0385","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.10.016_bb0390","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1002\/1529-0131(200011)43:11<2402::AID-ANR5>3.0.CO;2-C","article-title":"Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study","volume":"43","author":"Spiegel","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.10.016_bb0395","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0400","first-page":"1670","article-title":"Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis","volume":"28","author":"Pignatti","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2018.10.016_bb0405","first-page":"28","article-title":"IL1RN variation influences both disease susceptibility and response to recombinant human interleukin-1 receptor antagonist therapy in systemic juvenile idiopathic arthritis","volume":"2","author":"Arthur","year":"2018","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.10.016_bb0410","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0415","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/rheumatology\/kew300","article-title":"Elevated serum levels of free interleukin-18 in adult-onset Still's disease","volume":"55","author":"Girard","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2018.10.016_bb0420","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.10.016_bb0425","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.10.016_bb0430","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.det.2013.04.003","article-title":"Autoinflammatory diseases in pediatrics","volume":"31","author":"Hausmann","year":"2013","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.clim.2018.10.016_bb0435","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nature13788","article-title":"Dietary modulation of the microbiome affects autoinflammatory disease","volume":"516","author":"Lukens","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.clim.2018.10.016_bb0440","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/annrheumdis-2016-210324","article-title":"Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications","volume":"76","author":"Ombrello","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.10.016_bb0445","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMra1615014","article-title":"Classification, ontology, and precision medicine","volume":"379","author":"Haendel","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618304327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661618304327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T22:10:18Z","timestamp":1775254218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661618304327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":89,"alternative-id":["S1521661618304327"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2018.10.016","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting cytokines to treat autoinflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2018.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}